Literature DB >> 22478720

MS: Prevalence, Economics, and the Pipeline.

Lola Butcher.   

Abstract

Prevalence of disease, economics of care, and implications for payers, as told in charts.

Year:  2008        PMID： 22478720      PMCID： PMC2706182     

Source DB:  PubMed          Journal:  Biotechnol Healthc        ISSN： 1554-169X


  3 in total

1.  Cost-effectiveness of four immunomodulatory therapies for relapsing-remitting multiple sclerosis: a Markov model based on long-term clinical data.

Authors:  Christopher Bell; Jonathan Graham; Stephanie Earnshaw; Merrikay Oleen-Burkey; Jane Castelli-Haley; Kenneth Johnson
Journal:  J Manag Care Pharm       Date:  2007-04

2.  Costs and quality of life in multiple sclerosis: a cross-sectional study in the United States.

Authors:  Gisela Kobelt; Jenny Berg; Deborah Atherly; Olympia Hadjimichael
Journal:  Neurology       Date:  2006-06-13       Impact factor: 9.910

3.  The Sonya Slifka Longitudinal Multiple Sclerosis Study: methods and sample characteristics.

Authors:  S L Minden; D Frankel; L Hadden; J Perloffp; K P Srinath; D C Hoaglin
Journal:  Mult Scler       Date:  2006-02       Impact factor: 6.312
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.